UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported) May 31,
2017
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
000-00935
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
4203 SW 34th St.
|
|
|
Orlando,
FL
|
32811
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off Balance Sheet Arrangement of a
Registrant
On May 31, 2017, Medite GmbH (“Medite”), a wholly-owned
subsidiary of MEDITE Cancer Diagnostics, Inc. (the
“Company”) entered in an agreement
with VR
Equity Partner GmbH (formerly DZ Equity Partners) to extend the payment date of a credit facility in
the outstanding principal amount of EUR 750,000 until September 1,
2017. In consideration for the extension, Medite shall pay an
interest increase on the outstanding principal balance of three
percent (3%).
Item 8.01 Other Events
On May 31, 2017, MEDITE Cancer Diagnostics, Inc. (the
“Company”) exercised its discretionary election to
extend the Closing Date of its current private placement offering
of up to $4,250,000 from May 31, 2017, until June 30, 2017, as
provided in the Securities Purchase Agreement, as
amended.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
June 6, 2017
|
By:
|
/s/ David E. Patterson
|
|
|
|
David
E, Patterson
|
|
|
|
Chief
Executive Officer
|
|
|